Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. (CPRX) Stock Overview

Explore Catalyst Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

CPRX●NASDAQ
HealthcareBiotechnology
$31.49
$0.00(0.00%)
U.S. Market opens in 61h 45m

Catalyst Pharmaceuticals, Inc. (CPRX)

Meyka AI Score

Z

Key Financials

Market Cap3.9B
P/E Ratio17.49
EPS (TTM)$2.56
ROE0.24%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 Months$33.73
1 Year Target$29.96

CPRX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Catalyst Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of CPRX on the NASDAQ shows an RSI of 65.57, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $29.96 for the NASDAQ listing.

Key metrics behind Catalyst Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of 17.49 and a market capitalization of 3.9B. Combined with our AI analysis, these give both institutional and retail investors a clear view of CPRX on the NASDAQ.

Price Performance (NASDAQ: CPRX)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
1.06%
6-Month Change
29.43%
Year-to-Date (YTD) Change
34.92%
1-Year Change
56.90%
3-Year Change
111.91%
5-Year Change
451.49%
All-Time (Max) Change
416.23%

Contact Information

https://www.catalystpharma.com
305 420 3200
355 Alhambra Circle, Coral Gables, FL, 33134

Company Facts

1,820 Employees
IPO DateNov 8, 2006
CountryUS

Frequently Asked Questions